Acesse a bula do Ciprofibrato para saber tudo sobre o medicamento: para que serve, como tomar, contraindicações e efeitos colaterais. Learn about Ciprofibrato uses, dosage, side effects, food interactions, and more. Get all the details about Ciprofibrato from MedicinesFAQ. Bula do Ciprofibrato, conteúdo extraído da Anvisa e organizado por tópicos. Veja para que serve o Ciprofibrato, como usar, preços e mais. Ciprofibrate is a medicine available in a number of countries worldwide. A list of US medications equivalent to Ciprofibrate is available on the Drugs.com website. Ciprofibrate, known by its trade name Lipanor, is an oral lipid-lowering agent primarily prescribed to address conditions associated with high cholesterol levels, specifically hyperlipidemia and hypertriglyceridemia. It belongs to the class of medications known as fibrates. We get Ciprofibrate from fibric acid. High cholesterol and high triglycerides are considered harmful to our heart health. Ciprofibrate can lower cholesterol and triglyceride levels in the blood. Also, it increases the level of good cholesterol, high-density lipoprotein (HDL), in our body. - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. The recommended dosage is one tablet (100mg ciprofibrate) per day. This dose should not be exceeded (see Precautions). As for adults, but see Precautions and Warnings. Take one (100 mg) tablet daily. Some lifestyle changes will also help to reduce your lipid level - eat healthy food, stop smoking, increase the exercise you take, and reduce the amount of salt in your diet. If you develop any unusual aches and pains in your muscles, contact your doctor for advice. Ciprofibrate is a lipid-lowering agent that belongs to the class of drugs known as fibrates. It is primarily used to treat hyperlipidemia, a condition characterized by elevated levels of lipids (fats) in the blood. Ciprofibrate is a fibrate that was developed as a lipid-lowering agent. It was patented in 1972 and approved for medical use in 1985. [1] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495. This drug article relating to the cardiovascular system is a stub.